Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tablets
⚡ Quick Summary
Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval for rheumatoid arthritis and other conditions is expected to bolster its U.S.
📰 Related Articles
Reps demand probe, relief for victims of deadly Bauchi community clash
Punch Nigeria
Police arrest suspected drug baron, recover stolen items in A’Ibom
Punch Nigeria
Gunmen abduct Osun LG vice chairman
Punch Nigeria
Nigerian jailed in US for using fake identity to secure job
Punch Nigeria
PMD forecasts dust and windstorms, thunderstorms across most parts of the country from June 11–13
Dawn Pakistan